Zomer E - Search Results

1

Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia.

Hastings K, Marquina C, Morton J, Abushanab D, Berkovic D, Talic S, Zomer E, Liew D, Ademi Z. Hastings K, et al. Among authors: zomer e. Pharmacoeconomics. 2022 Apr;40(4):449-460. doi: 10.1007/s40273-021-01127-1. Epub 2022 Jan 17. Pharmacoeconomics. 2022. PMID: 35037191 Free PMC article.

2

Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the 'old' versus the 'new' Framingham equation.

Zomer E, Owen A, Magliano DJ, Liew D, Reid C. Zomer E, et al. Eur J Cardiovasc Prev Rehabil. 2011 Feb;18(1):115-20. doi: 10.1097/HJR.0b013e32833ace24. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 20473180

3

Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.

Zomer E, Liew D, Owen A, Magliano DJ, Ademi Z, Reid CM. Zomer E, et al. Eur J Prev Cardiol. 2014 Mar;21(3):384-90. doi: 10.1177/2047487312449307. Epub 2012 May 15. Eur J Prev Cardiol. 2014. PMID: 22588087

4

The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model.

Zomer E, Owen A, Magliano DJ, Liew D, Reid CM. Zomer E, et al. BMJ. 2012 May 30;344:e3657. doi: 10.1136/bmj.e3657. BMJ. 2012. PMID: 22653982 Free PMC article.

5

Overview of pharmacoeconomic modelling methods.

Ademi Z, Kim H, Zomer E, Reid CM, Hollingsworth B, Liew D. Ademi Z, et al. Among authors: zomer e. Br J Clin Pharmacol. 2013 Apr;75(4):944-50. doi: 10.1111/j.1365-2125.2012.04421.x. Br J Clin Pharmacol. 2013. PMID: 22882459 Free PMC article. Review.

6

Outcomes and excess costs among patients with cardiovascular disease.

Ademi Z, Liew D, Zomer E, Gorelik A, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. Ademi Z, et al. Among authors: zomer e. Heart Lung Circ. 2013 Sep;22(9):724-30. doi: 10.1016/j.hlc.2013.02.002. Epub 2013 Mar 17. Heart Lung Circ. 2013. PMID: 23510668 Clinical Trial.

7

Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.

Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D. Zomer E, et al. Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2. Am J Cardiovasc Drugs. 2013. PMID: 23532687

8

Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data.

Ademi Z, Liew D, Gorelik A, Bohensky M, Zomer E, Hollingsworth B, Steg G, Bhatt DL, Reid CM; REACH Registry investigators. Ademi Z, et al. Among authors: zomer e. Int J Cardiol. 2014 Jul 15;175(1):72-7. doi: 10.1016/j.ijcard.2014.04.230. Epub 2014 Apr 28. Int J Cardiol. 2014. PMID: 24816526

9

Can oral vitamin D prevent the cardiovascular diseases among migrants in Australia? Provider perspective using Markov modelling.

Ruwanpathirana T, Owen A, Renzaho AM, Zomer E, Gambhir M, Reid CM. Ruwanpathirana T, et al. Among authors: zomer e. Clin Exp Pharmacol Physiol. 2015 Jun;42(6):596-601. doi: 10.1111/1440-1681.12399. Clin Exp Pharmacol Physiol. 2015. PMID: 25854647

10

Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.

Zomer E, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Zomer E, et al. Diabetes Obes Metab. 2017 Jan;19(1):118-124. doi: 10.1111/dom.12792. Epub 2016 Oct 20. Diabetes Obes Metab. 2017. PMID: 27649286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters